Pancreatic Cancer Research

ResearcherTianjin UniversityNo recent work listed

He Huang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3008-4869; OpenAlex author ID A5088996718. Sources: OpenAlex.

Their work

Papers
3 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
7
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 1 paper

Papers 3

  1. VHH212 nanobody targeting the hypoxia-inducible factor 1α suppresses angiogenesis and potentiates gemcitabine therapy in pancreatic cancer in vivo. Last author DOI 10.20892/j.issn.2095-3941.2020.0568↗
  2. Inhibition of autophagy strengthens celastrol-induced apoptosis in human pancreatic cancer in vitro and in vivo models. Co-author DOI 10.2174/1566524014666140414211223↗
  3. Polymorphisms in the hypoxia-inducible factor-1α gene confer susceptibility to pancreatic cancer. Co-author DOI 10.4161/cbt.12.5.15982↗

Closest collaborators

The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. He Ren · 2 shared papers, 2011–2021 · strength 0.15
  2. Guangbo Kang · 1 shared paper, 2021 · strength 0.13
  3. Xingyu Zhao · 1 shared paper, 2014 · strength 0.05
  4. J H Hao · 1 shared paper, 2014 · strength 0.05
  5. Xiuchao Wang · 1 shared paper, 2011 · strength 0.02
  6. Tiansuo Zhao · 1 shared paper, 2011 · strength 0.02
  7. Jihui Hao · 1 shared paper, 2011 · strength 0.02

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.